News
Patients treated with Xarelto (rivaroxaban; Janssen) for deep vein thrombosis (DVT) had less frequent hospital admissions than those treated with standard low molecular weight heparin (LMWH) and warfarin, according to study data presented at the Hospital Medicine 2015 Congress.
News
Boston Scientific announced that the Food and Drug Administration (FDA) has approved WATCHMAN Left Atrial Appendage Closure Device to reduce the risk of stroke in high-risk patients with non-valvular atrial fibrillation who are looking for an alternative to long-term warfarin therapy.
News
Co-treatment with proton-pump inhibitors (PPIs) in patients initiating warfarin was associated with reduced reduced risk of warfarin-related upper gastrointestinal (GI) bleeding, a study published in Gastroenterology reported.
News
A retrospective cohort study in the Annals of Pharmacotherapy found a clinically significant decrease in warfarin dose-response with concurrent hepatitis C treatments, especially with ombitasvir/paritaprevir/ritonavir and dasabuvir (OBV-PTV/r-DSV).
News
A study published in JAMA found that warfarin use to prevent strokes in atrial fibrillation may not adequately manage blood clotting over time, despite patients having been stable on the drug.
News
The greatest risk reduction of stroke or systemic embolism was seen with dabigatran 150mg twice daily (odds ratio [OR] 0.65, 95% CI: 0.52-0.81), followed by apixaban 5mg twice daily (OR 0.79, 95% CI: 0.66-0.94).
News
Findings from a recent study suggests that clinical and genetic factors affecting warfarin dose requirements differ by race.
News
Findings from a study published in the British Journal of Clinical Pharmacology showed that apixaban appeared to be an appropriate alternative to warfarin for patients with severe renal impairment.
News
Results from a real-world study evaluating rivaroxaban (Xarelto; Janssen) in newly diagnosed patients with nonvalvular atrial fibrillation (NVAF) were presented at the American College of Cardiology's (ACC) 68th Annual Scientific Session.
News
In patients with a first episode of pulmonary embolism who took six months of anticoagulants, another 18 months of treatment with warfarin reduced the risk of blood clots and major bleeding, though the benefit was not maintained after discontinuing anticoagulation therapy, a study has shown.
